ASH Annual Meeting 2021
Advertisement
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Damon E. Houghton, MD, MS, of Mayo Clinic in Rochester, Minnesota, presented the data at the ASH Annual Meeting 2021.
This lack of benefit was seen in the entire study population.
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.
“The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma."
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care.
This clinical outcome translates to meaningful improvement in health-related quality of life, according to researchers.
Researchers evaluated the effects of etavopivat in two-week multiple ascending dose cohorts and a 12-week open-label study.
Researchers found no increased risk for acute deep vein thrombosis post-vaccination for approved COVID-19 vaccines.
Lead author Jacqueline N. Poston, MD, shared the findings.
The present analysis updates findings from the ongoing phase 1/2 HGB-206 study.
Researchers described the outcomes for pregnant women with SCD, who are considered at high risk for complications.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.